title: 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.
abstract: Ambulatory blood pressure monitoring (ABPM) allows determining of the nocturnal blood pressure fall (NBPF). An NBPF below 10% (nondipper pattern) has been related to increased cardiovascular risk, and it is a common finding in type 2 diabetic hypertensive patients. The authors evaluated the impact on 24-hour blood pressure, NBPF, and albuminuria of olmesartan 40 mg, administered in a morning- vs a nocturnal-based dosing scheme, in type 2 diabetic patients with newly diagnosed hypertension. Using a crossover design, 40 patients (42.1% men) received olmesartan 40 mg once daily at wake up or bedtime for 8 weeks. Patients underwent 24-hour ABPM at baseline and at weeks 8 and 16, and albumin to creatinine ratio was measured at baseline and 8 weeks. Night systolic blood pressure (BP) (P=.007) and mean BP (P=.012) were significantly reduced following the bedtime dose, compared with morning dosing. Night BP fall (%) was significantly reduced by bedtime dosing, compared with morning dosing (P=.0001). No differences were seen for urinary albumin excretion between both arms at week 8. Without affecting 24-hour BP control, night dosing of olmesartan increases nocturnal BP fall significantly more than conventional morning dosing, increasing the number of dipper diabetic hypertensive patients.
authors.affiliation: Service of Endocrinology, Centro Médico Juaneda, Inca, Spain. santiago.tofe@ssib.es
authors.forename: Santiago
authors.initials: S
authors.lastname: Tofé Povedano
authors.forename: Bernardo
authors.initials: B
authors.lastname: García De La Villa
mesh_terms: D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000652:urine; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D002940:Circadian Rhythm / Q000502:physiology*; D003404:Creatinine / Q000652:urine; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology* / Q000652:urine; D007093:Imidazoles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D013777:Tetrazoles; C437965:olmesartan; D003404:Creatinine
references.citation: JAMA. 2001 Jul 25;286(4):421-6
references.pmid: 11466120
references.citation: Chronobiol Int. 2001 Jan;18(1):109-21
references.pmid: 11247110
references.citation: Diabet Med. 2000 May;17(5):360-4
references.pmid: 10872534
references.citation: Hypertension. 2007 Oct;50(4):715-22
references.pmid: 17635851
references.citation: Am J Hypertens. 1994 Sep;7(9 Pt 1):808-13
references.pmid: 7811439
references.citation: J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4 Suppl 1):3-8
references.pmid: 12147922
references.citation: Theor Biol Med Model. 2006 Jan 10;3:1
references.pmid: 16403216
references.citation: JAMA. 2003 May 21;289(19):2560-72
references.pmid: 12748199
references.citation: Circulation. 2003 Mar 18;107(10):1401-6
references.pmid: 12642361
references.citation: Eur J Clin Pharmacol. 1988;33(6):619-24
references.pmid: 3366165
references.citation: Diabetes Care. 2003 Jan;26 Suppl 1:S80-2
references.pmid: 12502624
references.citation: Pharmacol Ther. 2006 Sep;111(3):629-51
references.pmid: 16480770
references.citation: Diabetes Care. 2002 Dec;25(12):2218-23
references.pmid: 12453964
references.citation: Nephrol Dial Transplant. 1998 Mar;13(3):635-9
references.pmid: 9550639
references.citation: Diabetes. 1993 Dec;42(12):1745-52
references.pmid: 8243821
references.citation: Hypertension. 2008 Jan;51(1):69-76
references.pmid: 17968001
references.citation: N Engl J Med. 2001 Sep 20;345(12):851-60
references.pmid: 11565517
references.citation: Expert Opin Ther Targets. 2008 Oct;12(10):1257-63
references.pmid: 18781824
references.citation: J Hypertens. 2005 Oct;23(10):1913-22
references.pmid: 16148616
references.citation: Circulation. 2004 Jul 6;110(1):32-5
references.pmid: 15210602
references.citation: J Hypertens. 2008 Nov;26(11):2191-7
references.pmid: 18854760
references.citation: Hypertens Res. 2004 Jan;27(1):15-20
references.pmid: 15055251
references.citation: N Engl J Med. 2001 Sep 20;345(12):861-9
references.pmid: 11565518
references.citation: Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):923-39
references.pmid: 17659803
references.citation: Am J Cardiovasc Drugs. 2005;5(1):7-15
references.pmid: 15631533